Daiichi’s Japan Filing The First For Denosumab In RA
Daiichi Sankyo has filed for the approval in Japan of denosumab for rheumatoid arthritis, marking the first such filing for the Amgen-originated antibody in this setting.
You may also be interested in...
A few weeks after its R&D alliance in Japan with Takeda was scaled back, Amgen has found a new partner in the country, this time for the commercialization of a broad portfolio of biosimilars.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.